The appearance of angiotensin receptor blockers (ARBs) amongst the therapeutic options in the treatment of cardiovascular diseases (CVDs) was a new milestone in the history of hypertension treatment. It further widened the range of possibilities for personalized therapy, especially for patients who cannot tolerate the use of angiotensin converting enzyme inhibitors (ACEIs). Continue reading
Drug-food interactions are a significant problem in clinical practice. Foods may alter the effects of drugs by interfering with pharmacokinetic processes, such as absorption and elimination.